We invite you to read the sources below to learn more about CAR T-cell therapy for multiple myeloma. 

News articles and pages

• Real-World CAR T Data for Extramedullary Patients
• What’s Better for High-Risk Multiple Myeloma? Cilta-cel vs Standard of Care
• The Use of Bispecifics and CAR-T in Myeloma Treatment
• Two Myeloma CAR T Therapies Receive FDA Approval for Earlier Use
• New Target for Relapsed Myeloma: LILRB4-directed CAR-T Therapy
• How CAR-T Therapy is Changing the Treatment Landscape for Myeloma
• An ODAC Meeting for Carvykti (CAR-T) for Multiple Myeloma Treatment Announced
• Cell Features Key to Targeting Myeloma Cells: BCMA Directed Therapies
• Could CAR-T Therapy Be Given By Direct Injection?
• Physicians Take on CAR-T Therapy Secondary Cancer Risks
• CAR T Therapy Gets First European Approval in Earlier Lines for Multiple Myeloma
• An ODAC Meeting for Abecma (CAR-T) for Triple-Class Exposed Multiple Myeloma
• My CAR-T Therapy Experience: A Myeloma Patient Story
• ASH 2023: How Can Relapsed/Refractory Myeloma Outcomes Improve in 2024?
• ASH 2023: The Effect of Stem Cell Infusion on ICAHT after CAR-T Cell Therapy
• ASH 2023: Raising the BCMA Standard in Multiple Myeloma

HealthTree University (HTU) videos

• Myeloma CAR-T UNIT
• How are IMiDs and CELMoDs being explored in combination with CAR T-cell therapy?
• What is being done to enhance the response of CAR-T cell therapy and bispecific antibody therapy?
• What factors should be considered when choosing between a CAR T cell therapy and a bispecific antibody therapy?
• What types of infections have been seen with CAR-T and BsAb therapy? Why are these infections prevalent? How are serious infections mitigated after CAR T cell and BsAb therapy?
• HTU Myeloma Specialist Conference Interviews on CAR-T
  • Building a Myeloma-Specific Score to Predict CAR-T Therapy Toxicities | Utkarsh Goel MD
  • Update on BMS-986393, a GPRC5D #Myeloma CAR-T | Susan Bal, MD
  • Treating High-Risk Smoldering Myeloma using CAR-T - CAR-PRISM Study | Omar Nadeem, MD
  • Post-CAR-T Driving Restrictions after Week 4 In Myeloma Appear Unnecessary | Rahul Banerjee
  • Beating T-Cell Exhaustion: The Future of Myeloma Care | Marta Chesi, PhD & Erin Meermeier, PhD
  • Boosting Infection Protection in Myeloma Patients with IvIG Therapy | Betsy O’Donnell, MD
  • ICAHT After CAR-T for Myeloma: a Stem Cell Boost Solution | Carolina Schinke, MD
  • CAR-T Therapy (ide-cel) Consolidation for Suboptimal ASCT Responders | Barry Paul, MD
  • Looking Back: Real-World Data on CAR-T and Bispecifics for RRMM | Natalia Neparidze, MD
  • CAR-T Efficacy for Myeloma Patients with Bispecific Exposure | Johannes Waldschmidt, MD
  • Anito-Cel, a novel anti-BCMA CAR T-cell, for Relapsed/Refractory Myeloma | Ciara Freeman, MD
  • Anti-BCMA CAR-T Resistance in Myeloma: Genomic Predictors | Francesco Maura, MD
  • Genomic Determinants of Resistance to Anti-BCMA CAR-T Therapies in Myeloma | Ciara Freeman
  • MRD Results from Cartitude-4 (Cilta-Cel vs SOC) in RRMM | Rakesh Popat
  • Phase 1 Study of Antio-cel, an Anti-BCMA CAR-T, for RRMM | Michael Bishop, MD
  • Late Complications and Long-term Care of CAR T-cell Patients | Michael Bishop, MD
  • Minority Access & Outcomes with Anti-BCMA CAR T Therapy in Myeloma | Luca Paruzzo, MD
  • Furthering Our Understanding of Delayed Neurotoxicity Post CAR-T in MM | Anupama Kumar, MD
  • Delayed Neutrophil Recovery Following BCMA-Directed CAR-T in Myeloma | Zachary Avigan, MD

Event recordings 

• The Efficacy of CAR-T Therapy in High-Risk Patients and Strategies to Improve Outcomes
• RESCHEDULED: Real-World CAR-T Data Update
• T-Cell Re-Direction Therapy | Bay Area RT March 9, 2024
• The History and Promise of CAR-T | Miami RoundTable April 20, 2024
• Using CAR-T Therapy Strategically in Myeloma Care | Charlotte Roundtable, May 4th, 2024
• The Evolving World of Immunotherapies | Detroit RoundTable October 12, 2024
• Relapsed/Refractory Multiple Myeloma | New York Roundtable October 19, 2024
• CAR-T Therapy in Multiple Myeloma | Dallas Roundtable November 2, 2024